FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225422085> ?p ?o ?g. }

• W4225422085 abstract "The worsening opioid epidemic has highlighted the need for the development of new, safe, and effective analgesic therapeutics. Opioid therapy currently is associated with the risk of conversion to addiction, diversion from patients for whom use is intended, and the development of analgesic tolerance, or the loss of efficacy with continued treatment. To this end, we have developed a line of non-opioid, agmatine-based compounds and assessed them for their efficacy in reversing behavioral expressions of pain in animal models, as well as evaluated their safety following chronic exposure. We have previously shown that agmatine, decarboxylated L-arginine, is an N-methyl-D-aspartate (NMDA) receptor antagonist that preferentially antagonizes receptors that express NR2B subunits. This preferential antagonism is desirable for NMDA-based therapeutics as it can lead to a widening of the therapeutic window and avoidance of the side effects commonly associated with NMDA antagonism including motor ataxia and psychoactive effects. However, agmatine has shown limited penetration through the blood brain barrier (BBB) and a short systemic half-life, limiting its clinical utility. We have designed strategically-substituted agmatine (SSA) compounds with the goal of improving its penetration through the BBB by increasing the lipophilicity of agmatine, potentially improving distribution across the BBB and increasing its half-life following systemic delivery. To this end, we have evaluated this series of SSAs for safety and efficacy in multiple animal models of pain. Mice (21-30 g, M/F) were assessed for their baseline mechanical sensitivity, and then one of several models of pain was induced: inflammatory pain (Complete Freund's Adjuvant, (CFA) injected into a hindpaw), neuropathic pain (spared nerve injury surgery), or post-surgical pain (hindpaw muscle incision). Mechanical sensitivity was again assessed, then an SSA compound, agmatine (the parent compound), or vehicle control was administered, and mechanical sensitivity was recorded for up to three hours following administration. The SSA compounds effectively reversed pain behaviors in mice following administration in the various pain models. Additionally, side effects characteristic of NMDA receptor antagonists were assessed and not found at the range of doses that produced analgesia, indicating a wide therapeutic window. These data indicate that the strategically-substituted agmatines are anti-hyperalgesic compounds with a wide therapeutic window, avoiding the motor impairment typical of drugs of this class." @default.
• W4225422085 created "2022-05-05" @default.
• W4225422085 creator A5019747808 @default.
• W4225422085 creator A5023725612 @default.
• W4225422085 creator A5069041434 @default.
• W4225422085 creator A5079914120 @default.
• W4225422085 date "2022-05-01" @default.
• W4225422085 modified "2023-10-12" @default.
• W4225422085 title "Characterization of Novel, Agmatine‐Based NMDA Receptor Antagonists in Multiple Pain States" @default.
• W4225422085 doi "https://doi.org/10.1096/fasebj.2022.36.s1.r5090" @default.
• W4225422085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35560903" @default.
• W4225422085 hasPublicationYear "2022" @default.
• W4225422085 type Work @default.
• W4225422085 citedByCount "0" @default.
• W4225422085 crossrefType "journal-article" @default.
• W4225422085 hasAuthorship W4225422085A5019747808 @default.
• W4225422085 hasAuthorship W4225422085A5023725612 @default.
• W4225422085 hasAuthorship W4225422085A5069041434 @default.
• W4225422085 hasAuthorship W4225422085A5079914120 @default.
• W4225422085 hasConcept C118552586 @default.
• W4225422085 hasConcept C126322002 @default.
• W4225422085 hasConcept C15490471 @default.
• W4225422085 hasConcept C170493617 @default.
• W4225422085 hasConcept C185592680 @default.
• W4225422085 hasConcept C2777468819 @default.
• W4225422085 hasConcept C2779245659 @default.
• W4225422085 hasConcept C2780820201 @default.
• W4225422085 hasConcept C2781063702 @default.
• W4225422085 hasConcept C2781118164 @default.
• W4225422085 hasConcept C2781448169 @default.
• W4225422085 hasConcept C42219234 @default.
• W4225422085 hasConcept C515207424 @default.
• W4225422085 hasConcept C55493867 @default.
• W4225422085 hasConcept C67018056 @default.
• W4225422085 hasConcept C71924100 @default.
• W4225422085 hasConcept C98274493 @default.
• W4225422085 hasConceptScore W4225422085C118552586 @default.
• W4225422085 hasConceptScore W4225422085C126322002 @default.
• W4225422085 hasConceptScore W4225422085C15490471 @default.
• W4225422085 hasConceptScore W4225422085C170493617 @default.
• W4225422085 hasConceptScore W4225422085C185592680 @default.
• W4225422085 hasConceptScore W4225422085C2777468819 @default.
• W4225422085 hasConceptScore W4225422085C2779245659 @default.
• W4225422085 hasConceptScore W4225422085C2780820201 @default.
• W4225422085 hasConceptScore W4225422085C2781063702 @default.
• W4225422085 hasConceptScore W4225422085C2781118164 @default.
• W4225422085 hasConceptScore W4225422085C2781448169 @default.
• W4225422085 hasConceptScore W4225422085C42219234 @default.
• W4225422085 hasConceptScore W4225422085C515207424 @default.
• W4225422085 hasConceptScore W4225422085C55493867 @default.
• W4225422085 hasConceptScore W4225422085C67018056 @default.
• W4225422085 hasConceptScore W4225422085C71924100 @default.
• W4225422085 hasConceptScore W4225422085C98274493 @default.
• W4225422085 hasFunder F4320338273 @default.
• W4225422085 hasIssue "S1" @default.
• W4225422085 hasLocation W42254220851 @default.
• W4225422085 hasLocation W42254220852 @default.
• W4225422085 hasOpenAccess W4225422085 @default.
• W4225422085 hasPrimaryLocation W42254220851 @default.
• W4225422085 hasRelatedWork W1983069658 @default.
• W4225422085 hasRelatedWork W1998585698 @default.
• W4225422085 hasRelatedWork W2009383738 @default.
• W4225422085 hasRelatedWork W2381245045 @default.
• W4225422085 hasRelatedWork W2414357090 @default.
• W4225422085 hasRelatedWork W2418740540 @default.
• W4225422085 hasRelatedWork W2587647595 @default.
• W4225422085 hasRelatedWork W2775339757 @default.
• W4225422085 hasRelatedWork W286397303 @default.
• W4225422085 hasRelatedWork W4200177234 @default.
• W4225422085 hasVolume "36" @default.
• W4225422085 isParatext "false" @default.
• W4225422085 isRetracted "false" @default.
• W4225422085 workType "article" @default.